开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09939 开拓药业-B

未开盘 09-28 16:08:26

1.850

+0.005

+0.27%

最高1.860	最低1.800	成交量64.75万
今开1.845	昨收1.845	日振幅3.25%
总市值9.23亿	流通市值9.23亿	总股本4.99亿
成交额118.33万	换手率0.13%	流通股本4.99亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09939","market":"HK","secType":"STK","nameCN":"开拓药业-B","latestPrice":1.85,"timestamp":1790582906624,"preClose":1.845,"halted":0,"volume":647500,"delay":0,"changeRate":0.002710027100271065,"floatShares":499000000,"shares":499000000,"eps":-0.444906,"marketStatus":"未开盘","change":0.005,"latestTime":"09-28 16:08:26","open":1.845,"high":1.86,"low":1.8,"amount":1183307,"amplitude":0.03252,"askPrice":1.85,"askSize":23500,"bidPrice":1.8,"bidSize":3000,"shortable":0,"etf":0,"ttmEps":-0.463836,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1790645400000},"marketStatusCode":0,"adr":0,"listingDate":1590076800000,"exchange":"SEHK","adjPreClose":1.845,"openAndCloseTimeList":[[1790559000000,1790568000000],[1790571600000,1790582400000]],"volumeRatio":0.921184,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09939/","defaultTab":"news","newsList":[{"id":"2670232287","title":"上海思璞锐医药与默沙东达成全球独家授权 首付款4亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2670232287","media":"第一财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670232287?lang=zh_cn&edition=full","pubTime":"2026-09-28 19:59","pubTimestamp":1790596779,"startTime":"0","endTime":"0","summary":"【上海思璞锐医药与默沙东达成全球独家授权 首付款4亿美元】9月28日，上海思璞锐医药科技有限公司（SciBrunch Therapeutics Co., Ltd.，以下简称“思璞锐”）与默沙东（默沙东为美国新泽西州罗威市默克公司的公司商号）共同宣布，双方就在研口服KRAS G12D（ON）抑制剂SPR2015达成全球独家授权协议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609283885360447.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609283885360447.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","BK1161","09939","BK1515","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670344192","title":"再次突围！药ETF华宝（562050）标的指数逆市收红，器械巨头力挺，512170韧劲十足！医药抗跌力从何而来？","url":"https://stock-news.laohu8.com/highlight/detail?id=2670344192","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670344192?lang=zh_cn&edition=full","pubTime":"2026-09-28 19:46","pubTimestamp":1790595960,"startTime":"0","endTime":"0","summary":"医疗ETF华宝跟踪的中证医疗指数微跌0.14%。截至收盘，药ETF华宝、医疗ETF华宝标的指数市盈率TTM分别为29.12倍、30.46倍，位于近10年10.86%、25.44%分位点，估值水平处于历史相对低位。药ETF华宝、医疗ETF华宝基金经理张放指出，医药投资主线或正从前期的“低估修复”，转向“创新兑现”驱动，同时AIDD产业链提供新增结构性机会。医疗ETF华宝：医药医疗类ETF旗舰，二季报规模256.24亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-09-28/doc-initktpc3633274.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["562050","BK1161","512170","BK1515","09939","159938","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670823999","title":"甘肃农垦药物碱厂与广州安信医药有限公司座谈交流","url":"https://stock-news.laohu8.com/highlight/detail?id=2670823999","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670823999?lang=zh_cn&edition=full","pubTime":"2026-09-28 18:09","pubTimestamp":1790590140,"startTime":"0","endTime":"0","summary":"近日，广州安信医药有限公司核心研发团队到药物碱厂有限公司开展实地参观并座谈交流。公司领导班子及研发、注册、生产相关项目负责人和技术人员参加座谈。本次面对面深度交流，有效打通了上下游信息壁垒，进一步了解掌握了全国麻精药品市场信息，明确了公司在全球麻精药品市场定位，开拓了今后发展思路和方向。广州安信医药对药物碱厂在原料药领域的研发实力与合规体系给予充分肯定。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-09-28/doc-initktnz9654871.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","159938","BK1161","BK1515","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670235916","title":"劲方医药-B(02595)9月28日斥资318.55万港元回购11.6万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2670235916","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670235916?lang=zh_cn&edition=full","pubTime":"2026-09-28 17:53","pubTimestamp":1790589238,"startTime":"0","endTime":"0","summary":"智通财经APP讯，劲方医药-B(02595)发布公告，于2026年9月28日斥资318.55万港元回购11.6万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1501537.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","BK1574","09939","BK1515","02595","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670804152","title":"9月28日亚虹医药科技跌6.92%，国联医疗健康混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2670804152","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670804152?lang=zh_cn&edition=full","pubTime":"2026-09-28 16:42","pubTimestamp":1790584959,"startTime":"0","endTime":"0","summary":"证券之星消息，9月28日亚虹医药科技跌6.92%，收盘报13.71元，换手率2.83%，成交量16.16万手，成交额2.27亿元。重仓亚虹医药科技的公募基金请见下表：根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为国联基金的国联医疗健康混合A。国联医疗健康混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800021528.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK1574","159760","09939","BK1515","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670286537","title":"医药韧性凸显！药ETF华宝（562050）逆市飘红，丽珠集团涨停！医疗器械局部强势，迈瑞、联影携手走强","url":"https://stock-news.laohu8.com/highlight/detail?id=2670286537","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670286537?lang=zh_cn&edition=full","pubTime":"2026-09-28 13:11","pubTimestamp":1790572260,"startTime":"0","endTime":"0","summary":"制药板块顽强抗跌，场内唯一跟踪制药指数的药ETF华宝一度逆市飘红，创新药概念股丽珠集团涨停封板，健康元、康弘药业、普洛药业齐涨逾5%。把握超跌医药新机遇，投资工具关注：药ETF华宝：全市场唯一跟踪制药指数的ETF，“70%创新药+20%中药”独家配比，兼具创新药高成长及中药高股息。医疗ETF华宝：全市场医药医疗类ETF旗舰，Q2规模256.24亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-09-28/doc-initkarm3859610.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["PTH","159883","159938","BK1161","RSPH","09996","BK0188","IEIH","MEDX","562050","000513","BK1583","HART","09939","BK0187","BK1515","LGHT","GDOC","BK1574","MDEV","LNGR","BK1100","BK0239","AGNG","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670540232","title":"星昊医药（920017）57.52万股限售股将于9月28日解禁，占总股本0.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2670540232","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670540232?lang=zh_cn&edition=full","pubTime":"2026-09-28 08:01","pubTimestamp":1790553718,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，星昊医药于9月28日将有57.52万股限售股份解禁，为公司股权激励期权行权，占公司总股本0.46%。最近一年内，该股累计解禁22.88万股，占总股本的0.18%。本次解禁后，公司还有136.24万股限售股份，占总股本1.09%。星昊医药主营业务：公司是一家从事高端药物制剂研发产业化服务的创新型企业。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800002052.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK1161","BK1515","09939","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670401108","title":"股市必读：欧康医药新发布《投资者关系活动记录表》","url":"https://stock-news.laohu8.com/highlight/detail?id=2670401108","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670401108?lang=zh_cn&edition=full","pubTime":"2026-09-28 03:44","pubTimestamp":1790538255,"startTime":"0","endTime":"0","summary":"公司公告汇总投资者关系活动记录表成都欧康医药股份有限公司于2026年9月23日举行特定对象调研活动，回应募投项目产能利用率、未来三年发展战略、欧盟GMP证书应用、海外市场拓展、原材料采购价格波动应对、股东减持计划影响及植物提取物行业发展机遇等问题。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800001764.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","159938","09939","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670409528","title":"股市必读：迪哲医药新发布《迪哲医药：关于高级管理人员减持股份计划公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2670409528","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670409528?lang=zh_cn&edition=full","pubTime":"2026-09-28 01:30","pubTimestamp":1790530233,"startTime":"0","endTime":"0","summary":"截至2026年9月24日收盘，迪哲医药报收于56.45元，下跌6.31%，换手率1.41%，成交量6.52万手，成交额3.74亿元。公司公告汇总：迪哲医药5名高级管理人员拟合计减持不超过353,091股，占总股本不超过0.0760%，减持期间为2026年11月2日至2027年2月1日。财务总监吕洪斌、副总经理陈素勤、QINGBEI ZENG、HONCHUNG TSUI、SHIH-YING CHANG合计持有公司股份1,400,961股，占总股本0.3012%。因个人资金需求，上述人员拟通过集中竞价方式减持不超过其持股数量的25%，合计减持不超过353,091股，占公司总股本不超过0.0760%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800000875.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","09939","BK1161","159938","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670840938","title":"股市必读：津药药业新发布《津药药业股份有限公司关于上海上实（集团）有限公司及上海上实投资发展有限公司挂牌转让上海琉璃光医药发展有限公司100%股权的提示性公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2670840938","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670840938?lang=zh_cn&edition=full","pubTime":"2026-09-28 01:09","pubTimestamp":1790528951,"startTime":"0","endTime":"0","summary":"公司公告汇总津药药业股份有限公司关于上海上实（集团）有限公司及上海上实投资发展有限公司挂牌转让上海琉璃光医药发展有限公司100%股权的提示性公告上海上实（集团）有限公司及上海上实投资发展有限公司通过上海联合产权交易所公开挂牌转让上海琉璃光医药发展有限公司100%股权，信息披露起止日期为2026年9月24日至2026年10月29日。本次股权转让事项已依法依规进行信息正式披露，津药药业将密切关注进展并履行信息披露义务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800000737.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","BK0028","BK0012","BK0239","09939","BK1161","BK0102","BK1515","600488","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670409924","title":"年内外资调研A股公司近6000次 外资机构调研路径呈现科技为主，消费、医药为辅的格局","url":"https://stock-news.laohu8.com/highlight/detail?id=2670409924","media":"东方财富网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670409924?lang=zh_cn&edition=full","pubTime":"2026-09-28 00:39","pubTimestamp":1790527140,"startTime":"0","endTime":"0","summary":"近日，为吸引更多境外中长期资金入市，促进国际投资者对沪市公司投资价值的了解，推动资本市场高水平对外开放，上交所再次组织开展“国际投资者赴境内调研上市公司”活动。来自英国、法国、新加坡等国近20家国际资管机构代表走进沪市科创企业一线，感受沪市科创企业坚实的经营基本面与多元增长动力。今年以来，外资机构调研A股上市公司的次数持续攀升。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"east_money_stock","url":"http://stock.eastmoney.com/news/11215,202609283884541543.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.eastmoney.com/news/11215,202609283884541543.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"east_money_stock","symbols":["09939","BK1515","02846","07233","82846","BK1147","BK1161","03130","02827","159938","02843","BK1610","399300","82822","83130","82823","83188","02823","02822","BK1574","82843","03188","159982"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670401559","title":"国泰海通｜医药：WCLC大会：中国公司展现强劲竞争力","url":"https://stock-news.laohu8.com/highlight/detail?id=2670401559","media":"国泰君安证券研究","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670401559?lang=zh_cn&edition=full","pubTime":"2026-09-27 22:33","pubTimestamp":1790519580,"startTime":"0","endTime":"0","summary":"报告导读：本次2026 WCLC大会，众多中国公司携旗下创新药亮相，展现出强大竞争力。回顾历年WCLC大会，中国研究占比持续提升。2026年WCLC大会于9/12-9/15举行，本次会议中国研究共有65项口头报告和2项主席讨论研究入选，近半数LBA报告为中国研究。本次WCLC大会康方生物发布了H2研究期中OS分析结果，亚组分析显示PV双抗AK112相比PD1单抗在高表达人群中有着更强的OS获益，且获益水平随着随访时间延长而提高。1L sqNSCLC：多种双抗展现竞争力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["research"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA5MzEwMDEzNQ==&mid=2650541863&idx=3&sn=812187e3743e09a590051f8c4e29f6a2&chksm=891507241be141023c1c9fadf89655283dfce65cfa3259143ba2581cdf28773942246335b65f&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["BK0012","BK0183","BK1564","BK0184","BK0188","BK0028","BK0276","BK1161","09939","601211","BK1574","02611","BK1147","159938","BK0201","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670419940","title":"迪哲医药（688192）9月24日主力资金净卖出1437.14万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2670419940","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670419940?lang=zh_cn&edition=full","pubTime":"2026-09-25 08:23","pubTimestamp":1790295809,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年9月24日收盘，迪哲医药报收于56.45元，下跌6.31%，换手率1.41%，成交量6.52万手，成交额3.74亿元。近5日资金流向一览见下表：迪哲医药融资融券信息显示，融资方面，当日融资买入2711.56万元，融资偿还3926.96万元，融资净偿还1215.39万元。迪哲医药主营业务：专注于肿瘤及血液系统疾病领域创新疗法的研究、开发和商业化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092500005096.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","688192","09939","159938","BK1515","BK1161","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670419954","title":"艾力斯医药科技（688578）9月24日主力资金净卖出344.76万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2670419954","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670419954?lang=zh_cn&edition=full","pubTime":"2026-09-25 08:22","pubTimestamp":1790295752,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年9月24日收盘，艾力斯医药科技报收于104.22元，下跌7.29%，换手率2.14%，成交量9.65万手，成交额10.26亿元。近5日资金流向一览见下表：艾力斯医药科技融资融券信息显示，融资方面，当日融资买入1.22亿元，融资偿还8534.22万元，融资净买入3647.45万元。艾力斯医药科技主营业务：专注于肿瘤治疗领域的创新药企业,目前已在非小细胞肺癌小分子靶向药领域构建了优势研发管线。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092500005077.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688578","BK1161","09939","159938","BK1515","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669460305","title":"迪哲医药：财务总监吕洪斌等多名高管拟减持股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2669460305","media":"同壁财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669460305?lang=zh_cn&edition=full","pubTime":"2026-09-24 18:23","pubTimestamp":1790245380,"startTime":"0","endTime":"0","summary":"同壁财经讯，迪哲医药发布最新公告称，公司财务总监吕洪斌、副总经理陈素勤、QINGBEIZENG、HONCHUNGTSUI、SHIH-YINGCHANG等五名高级管理人员因个人资金需求，计划在2026年11月2日至2027年2月1日期间，通过集中竞价方式减持部分股份。各人减持数量均不超过其各自当前持股的25%，股份主要来源于股权激励计划行权，吕洪斌另有部分股份来自二级市场增持。本次减持计划系高管个人资金需求的正常减持行为，不会对公司治理、持续经营等产生影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-09-24/doc-inisxtaz0277417.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","BK1161","BK1515","159938","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669146392","title":"9月24日益方生物科技跌5.83%，汇添富创新医药混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2669146392","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669146392?lang=zh_cn&edition=full","pubTime":"2026-09-24 16:38","pubTimestamp":1790239124,"startTime":"0","endTime":"0","summary":"证券之星消息，9月24日益方生物科技跌5.83%，收盘报18.75元，换手率1.84%，成交量10.68万手，成交额2.03亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共41家，其中持有数量最多的公募基金为汇添富基金的汇添富创新医药混合A。汇添富创新医药混合A目前规模为89.62亿元，最新净值1.72，较上一交易日下跌0.4%，近一年下跌14.37%。汇添富创新医药混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400028550.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","HBImain","09939","159938","BK1161","159837","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669463525","title":"劲方医药-B(02595)：陶莎辞任非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2669463525","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669463525?lang=zh_cn&edition=full","pubTime":"2026-09-24 16:33","pubTimestamp":1790238802,"startTime":"0","endTime":"0","summary":"智通财经APP讯，劲方医药-B(02595)发布公告，陶莎女士(陶女士)因个人工作事务，已辞任非执行董事，自2026年9月24日起生效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1500438.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","159938","09939","02595","BK1161","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669506724","title":"国药现代：青霉素类医药中间体及原料药出口地区主要以印度、韩国、泰国等亚洲国家，英国、法国等欧洲国家以及沙特阿拉伯等中东地区国家为主","url":"https://stock-news.laohu8.com/highlight/detail?id=2669506724","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669506724?lang=zh_cn&edition=full","pubTime":"2026-09-24 15:34","pubTimestamp":1790235265,"startTime":"0","endTime":"0","summary":"请问贵公司的青霉素中间体原料药除了日本，都销售发往了哪里？目前，公司青霉素类医药中间体及原料药出口地区主要以印度、韩国、泰国等亚洲国家，英国、法国等欧洲国家以及沙特阿拉伯等中东地区国家为主，暂无直接出口日本的业务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400021941.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0010","BK1574","BK0132","MNDmain","09939","159938","600420","BK1515","BK0082","BK0020","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669455191","title":"国盛证券：医药板块收入端仍承压 关注流感旺季催化","url":"https://stock-news.laohu8.com/highlight/detail?id=2669455191","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669455191?lang=zh_cn&edition=full","pubTime":"2026-09-24 11:09","pubTimestamp":1790219341,"startTime":"0","endTime":"0","summary":"下半年关注流感旺季带来的阶段性需求催化。","market":"fut","thumbnail":"https://img.zhitongcaijing.com/image/20260924/20260924104326_87256.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260924/20260924104326_87256.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1500311.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1574","BK0276","BK1161","BK1515","BK0052","09939","002670","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669378874","title":"劲方医药-B(02595)转仓市值总计9.12亿港元 占比9.11% 从中国证券登记结算香港转出2458.84万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2669378874","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669378874?lang=zh_cn&edition=full","pubTime":"2026-09-24 08:19","pubTimestamp":1790209186,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，9月23日，劲方医药-B出现仓位异动，转仓市值总计9.12亿港元，占比9.11%。该公司股东向中国国际金融香港证券转入878.2万股，从中国证券登记结算香港转出2458.84万股。该临床项目于2026年8月13日申请，公示截止日期为2026年9月24日。公司原计划根据市场惯例，于该临床项目正式纳入BTD名单后公告。但根据《上市规则》相关条文 ，特于现阶段公告此项拟纳入BTD名单的审评进展。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1500234.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02595","159938","BK1574","BK1515","09939","BK1161","161027"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kintor.com.cn","stockEarnings":[{"period":"1week","weight":-0.0263},{"period":"1month","weight":0.142},{"period":"3month","weight":-0.0314},{"period":"6month","weight":-0.2939},{"period":"1year","weight":-0.2227},{"period":"ytd","weight":-0.0561}],"compareEarnings":[{"period":"1week","weight":-0.016},{"period":"1month","weight":-0.0368},{"period":"3month","weight":0.077},{"period":"6month","weight":-0.0258},{"period":"1year","weight":-0.0569},{"period":"ytd","weight":-0.0385}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"开拓药业有限公司是一家主要从事创新药产品研发的投资控股公司。该公司产品致力于解决未满足临床需求的疾病领域，管线主要涵盖皮科（如脱发、痤疮等）及肿瘤适应症。该公司在皮科领域有两款核心药物KX-826及GT20029。该公司在其他疾病领域包括转移性去势抗性前列腺癌（mCRPC）、肝癌、特发性肺纤维化、恶性血液疾病及多种实体瘤等。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.020286},{"month":2,"riseRate":0.666667,"avgChangeRate":0.174983},{"month":3,"riseRate":0.333333,"avgChangeRate":0.058562},{"month":4,"riseRate":0.666667,"avgChangeRate":0.374359},{"month":5,"riseRate":0.5,"avgChangeRate":0.006013},{"month":6,"riseRate":0.285714,"avgChangeRate":-0.081543},{"month":7,"riseRate":0.571429,"avgChangeRate":0.098094},{"month":8,"riseRate":0.285714,"avgChangeRate":-0.060443},{"month":9,"riseRate":0.428571,"avgChangeRate":-0.098904},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.103242},{"month":11,"riseRate":0.666667,"avgChangeRate":0.073526},{"month":12,"riseRate":0.166667,"avgChangeRate":-0.185801}],"exchange":"SEHK","name":"开拓药业-B","nameEN":"KINTOR PHARMA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供开拓药业-B(09939)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"开拓药业-B,09939,开拓药业-B股票,开拓药业-B股票老虎,开拓药业-B股票老虎国际,开拓药业-B行情,开拓药业-B股票行情,开拓药业-B股价,开拓药业-B股市,开拓药业-B股票价格,开拓药业-B股票交易,开拓药业-B股票购买,开拓药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供开拓药业-B(09939)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}